Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

VRUS 0.0000
price chart
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
FOSTER CITY, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc.
Gilead to Acquire Pharmasset for $11 Billion to Add Hepatitis C Medicines  Bloomberg
Gilead could have had Pharmasset cheap: founder  Reuters
Related articles »  
Pharmasset Inc. (VRUS) President and CEO P Schaefer Price sells 20000 Shares
President and CEO of Pharmasset Inc. (VRUS) P Schaefer Price sells 20,000 shares of VRUS on 08/01/2011 at an average price of $120.15 a share.
Pharmasset Inc. Reports Operating Results (10-K)
Pharmasset Inc. has a market cap of $5.2 billion; its shares were traded at around $68.93 with and P/S ratio of 5095.7. Highlight of Business Operations: At least six major genotypes of HCV have been identified, each with multiple subtypes.
Pharmasset Reports Fiscal Year End 2011 Financial Results  PR Newswire (press release)
Related articles »  
Sovaldi patent case hits the UK courts � decision expected Q4 2014
Sofosbuvir was initially developed in the labs of an American company called Pharmasset. Pharmasset was bought by Gilead Sciences Inc. in 2012 for $11.1bn, despite a rather complex patent landscape and contractual claims over the rights to the ...
Sky-high price has VA rationing new hepatitis-C drug
Sanders said the biopharmaceutical company Gilead Sciences Inc., of Foster City, Calif., stands to earn more than $200 billion on a new drug called Sovaldi.
Gilead: What's Ahead In 2015 For This Biotech Juggernaut (GILD)  Seeking Alpha
Related articles »  
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to ...
Dr. Sommadossi is the principal founder of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) and a co-founder of Pharmasset, Inc. Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014, and Pharmasset by Gilead for $11.1 billion in ...
Related articles »  
Sky-high drug price has VA rationing new HEP-C drug
Sanders said the biopharmaceutical company Gilead Sciences Inc., of Foster City, Calif., stands to earn more than $200 billion on a new drug called Sovaldi.
OnCore Biopharma Closes Series R Financing
The Company was founded by former executives of Pharmasset, Inc., which was acquired by Gilead Sciences in January 2012.
Related articles »  
Halliburton Paying a Premium for Baker Hughes
The top three were: the Gilead Sciences Inc.GILD +0.82% acquisition of Pharmasset Inc.; Google Inc.GOOGL +1.32%'s purchase of Motorola Mobility Holdings Inc.; and BHP Billiton Ltd.
Related articles »  
Idenix hepatitis C drug patent, infringed but very invalid!
The recently issued judgement from Mr Justice Arnold in the matter of Idenix Pharmaceutical, Inc v Gilead Sciences, Inc & Ors, found Idenix's patent (EP 1523489), relating to particular compounds and their use in the treatment of hosts infected with a ...